Divergent effects of liraglutide, exendin-4, and sitagliptin on beta-cell mass and indicators of pancreatitis in a mouse model of hyperglycaemia by Mondragon, A et al.
Divergent Effects of Liraglutide, Exendin-4, and
Sitagliptin on Beta-Cell Mass and Indicators of
Pancreatitis in a Mouse Model of Hyperglycaemia
Angeles Mondragon1, Daniel Davidsson1, Styliana Kyriakoudi1, Annika Bertling1, Rosa Gomes-Faria1,
Patrizia Cohen2, Stephen Rothery3, Pauline Chabosseau1, Guy A. Rutter1, Gabriela da Silva Xavier1*
1 Section of Cell Biology, Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, Faculty of Medicine, Imperial College London, London, United
Kingdom, 2 Imperial College Healthcare NHS Trust, Department of Pathology, St. Mary’s Hospital, London, United Kingdom, 3 FILM, Imperial College London, London,
United Kingdom
Abstract
Aims: Glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP4) inhibitors improve glucose
tolerance by still incompletely understood mechanisms. Each class of antihyperglycemic drugs has also been proposed to
increase pancreatitis risk. Here, we compare systematically the effects of two widely-used GLP-1 analogues, liraglutide and
exendin-4, and the DPP4 inhibitor, sitagliptin, in the mouse.
Methods: C57BL6 mice were maintained for 131 days on a normal diet (ND) or a diet comprising 60% fat (HFD) before
measurements of fasting blood glucose and insulin, and intraperitoneal glucose tolerance. Beta- and alpha- cell volume, and
Reg3b immunoreactivity, were measured by immunohistochemical analysis of pancreatic slices.
Results: Whereas liraglutide (200 mg/kg) and exendin-4 (10 mg/kg) treatment reduced body weight and/or improved
glucose tolerance, sitagliptin (10 mg/kg) was without effect on either parameter. Liraglutide caused a sharp reduction in
beta-cell mass in both ND and HFD mice, whereas exendin-4 exerted no effect. By contrast, sitagliptin unmasked an action
of high fat diet to increase beta-cell mass. Reg3B positive area was augmented by all three agents in normal chow-fed mice,
whilst sitagliptin and exendin-4, but not liraglutide, affected this parameter in HFD animals. Correspondingly sitagliptin, but
not the GLP-1 analogues, increased circulating amylase levels in ND and HFD mice.
Conclusions: Liraglutide improves glucose tolerance in the mouse whilst exerting relatively modest effects on pancreatitis
risk. Conversely, exendin-4 and sitagliptin, at doses which exert, respectively, minor or no effects on metabolic parameters,
lead to signs of pancreatitis.
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Introduction
The incretin, glucagon-like peptide 1 (GLP-1), secreted after
meal ingestion from L-cells found primarily in the distal intestine
[1], promotes the secretion of insulin and somatostatin by
pancreatic beta- and delta- cells, respectively, and decreases
glucagon production from alpha-cells, as well as appetite and
gastric emptying Together with a suggested action on beta-cell
proliferation [2], and an absence of adverse effects such as weight
gain and hypoglycaemic episodes [3], GLP-1 is an ideal candidate
as a drug to treat type 2 diabetes (T2D)[4]. However, GLP-1 has a
short circulating half-life (,2 min) due to its rapid degradation by
dipeptidyl peptidase 4 (DPP-4), such that its therapeutic use
requires continuous administration or the engineering of GLP-1
mimetics with longer circulating life-times [5]. Consequently the
last decade has seen the development of two classes of GLP-1-
based drugs for T2D: GLP-1 receptor (GLP-1R) agonists that
mimic GLP-1 but are resistant to degradation by DPP-4, and
DPP-4 inhibitors.
Although an efficient drug class for the treatment of T2D [6],
recent data indicate that long-term administration of the GLP-1R
agonists and DPP4 inhibitors may be linked to an increased risk of
pancreatitis and pancreatic cancer [7–11]. The risk of pancreatic
cancer conferred by the usage of these anti-diabetic drugs is
difficult to assess as patients with a history of pancreatitis and
diabetes are in any case at increased risk of developing pancreatic
cancer [12,13]. Three commonly used agents are exenatide/
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exendin-4 and liraglutide, which are GLP-1 mimetics, and
sitagliptin, a DPP4 inhibitor.
The U.S. FDA issued a warning to healthcare professionals
about the possible increased risk of pancreatitis in T2D patients
taking sitagliptin following 88 cases of acute pancreatitis related
with sitagliptin use in 2009; pancreatitis was also associated with
exenatide use [14,15]. Subsequently, liraglutide, exendin-4 and
sitagliptin have all been variously associated with pancreatitis risk
in patients and rodent models [10,16–28] [29]. These results
raised concerns as chronic pancreatitis has been shown to increase
the risk of pancreatic cancer [26]. There is, nonetheless, a lack of
information from human pancreata; data from patients on long-
term treatment are not currently available, and the use of the
AERS to assess drug safety is arguably imperfect [9]. The evidence
for an association between GLP-1-based therapy and the
development of pancreatitis is intensified by the fact that all of
the developed agents which have been on the market long enough
have now been linked to cases of pancreatitis [17].
Although much has been published on the potential risk of
pancreatitis and pancreatic cancer from administration of GLP-1
mimetics, there have equally been studies which demonstrate no
effects on this parameter [30–38]. A recent study by Ellenbroek
and colleagues [39] demonstrated that mice administered liraglu-
tide prior to the start of a six-week long high fat diet regimen
remained normoglycaemic and exhibited decreased beta cell mass,
possibly due to improved insulin sensitivity. In total liraglutide’s
efficacy and safety have been investigated in more than 5000
patients through 20 clinical trials; in a number of these studies
markers of beta-cell function were also analysed leading to the
indication of improved beta-cell function [40,41], amongst other
potential beneficial effects [41–43]. The FDA and EMA exert
panels have also recently ruled that available data do not confirm
recent concerns over an increased risk for pancreatic side effects
with GLP-1-based diabetes therapies.
The aims of the present study were, therefore, to probe in a
mouse model of diet-induced glucose intolerance [44–46] the
propensity of the GLP-1 receptor agonists- liraglutide and
exendin-4- and the DPP4 inhibitor-sitagliptin- to cause signs of
pancreatitis, whilst comparing the action of each on weight gain,
glucose homeostasis and beta-cell mass.
Methods
Materials
All general chemicals and tissue culture reagents were
purchased from Sigma (Dorset, U.K.) or Invitrogen (Paisley,
U.K.), unless otherwise stated.
Animals
All in vivo procedures were approved by the U.K. Home Office
according to the Animals (Scientific Procedures) Act 1986 and
were performed at the Central Biomedical Service, Imperial
College, London, U.K. C57BL/6 male mice were purchased from
Charles River (U.K.). For high fat diet treatment, mice were
placed on a high fat diet at eight weeks of age for eight weeks (60%
[wt/wt] fat content; Research Diet, New Brunswick, NJ, USA).
Mice were housed at two to five animals per cage in a pathogen-
free facility with a 12-hour light-dark cycle. Animals were fed ad
libitum with a standard mouse chow diet (Research Diet, New
Brunswick, NJ) unless otherwise stated. Mice were culled by
cervical dislocation.
Intraperitoneal glucose tolerance test
Mice were fasted for 16 h, with water available ad libitum prior
to the test. Glucose tolerance tests were conducted at 09:00 on
each experimental day. Glucose tolerance was assessed by
intraperitoneal administration of glucose (1 g/kg).
Administration of GLP-1 mimetics
C57BL/6 mice (eight weeks old) were maintained on a normal
chow or high fat (60%; Lillico) diet for eight weeks prior to the
start of the injection regime. At 16 weeks of age, mice were
injected daily with saline, liraglutide (200 mg/kg [47]; Bachem,
Bubendorf, Switzerland), exendin-4 (10 mg/kg [27]; Polypeptide
Group SCI537 Strasbourg, France), or sitagliptin (10 mg/kg [48];
Sigma) at the start of the dark cycle.
Immunohistochemistry and widefield microscopy
Isolated pancreases were fixed in 10% buffered formalin and
embedded in paraffin wax within 24 h of removal. Head-to-tail
sections (5 mm lengthwise) were cut and incubated overnight at
37uC on superfrost slides. Slides were submerged sequentially in
Histoclear (Sigma) followed by decreasing concentrations of
industrial methylated spirits for removal of paraffin wax.
Permeabilised slices were blotted with primary antibodies against
insulin (DAKO, Cambridgeshire, U.K.), glucagon (Sigma) and
Reg3B (R&D Systems, Abingdon, U.K.) with antigen unmasking
using vector antigen unmasking solution (Vector Laboratories,
Peterborough, U.K.), and visualised with Alexa Fluor 488 or 568
secondary antibodies (Invitrogen). Specimens were mounted on
glass slides using Vectashield hard set with DAPI (Vector
Laboratories).
Images were captured on a Zeiss Axio Observer.Z1 Motorised
Inverted Widefield Microscope fitted with a Hamamatsu Flash 4.0
Camera using Plan-Apochromat 206/0.8 M27 air objective with
Colibri.2 LED illumination. Data acquisition was controlled by
Zeiss Zen Blue 2012 software configured at a bit depth of 16-bit
and binning mode 262.
Whole tissue tiled preview scans were obtained using an EC
Plan-Neofluar 106/0.3 Ph1 air objective with phase contrast. For
Reg3B analysis, a 20 point array was chosen at random with point
focusing achieved with the Plan-Apochromat 206/0.8 M27 air
objective using EGFP 488 filter as the reference channel for local
surface focusing.
Fluorescence quantification was achieved using Fiji [49].
Threshold measurements were taken for total tissue area using
particle size 200-infinity and fluorescence area using particle size
20-infinity for each of the 20 point arrays. Ratios were
subsequently calculated with an in-house macro for comparative
analyses between sample groups. We verified that our macro was
providing a measure of change in fluorescence through compar-
ison with manual scoring of the slides using an Nikon TS100-F
microscope fitted with a LED light source and appropriate filters
(Fig. S1; Nikon, London, U.K.). All image capture and analysis
were performed with the operator blinded to the identity of the
slides.
Measurement of plasma amylase, lipase and GLP-1
Blood (200 ml) was removed by cardiac puncture from mice
killed by cervical dislocation. Plasma was collected using high
speed (2000 g, 5 min at 4uC) centrifugation in heparin-coated
Microvette tubes containing EDTA (Sarstedt, Leicester, U.K.).
Plasma amylase and lipase levels were assessed using the lipase and
amylase assay kits from Abcam (Cambridge, U.K.). Plasma GLP-1
levels were assessed as previously described [45].
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Figure 1. Liraglutide and exendin-4 are effective weight management drugs in high fat-fed C57BL/6 mice, but liraglutide is more
effective at improving glucose tolerance. The weight of male C57BL/6 mice was monitored on a weekly basis over a period of eight weeks
(white area) on high fat (HFD) or normal chow diet (ND), followed by 75 days (grey area) of daily intraperitoneal injections of saline, or a GLP-1
mimetic- liraglutide (panels A–C), exendin-4 (panels D–F), or sitagliptin (panels G–I). Intra-peritoneal glucose tolerance tests were performed after 75
days of treatment (B–C, E–F, H–I). Time courses (B, E, H) and the corresponding areas under the curve (C, F, I) are shown. p#0.001, ***; p#0.01, **,
n = 3–7 mice.
doi:10.1371/journal.pone.0104873.g001
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Histopathology
Slices from pancreases prepared as detailed under ‘Immunohis-
tochemistry and widefield microscopy’ were stained with eosin and
haemotoxylin and subjected to histopathological analysis. Quali-
tative analysis of the following parameters were performed-
endocrine islet size variation and inflammation; cytoplasmic
vacuole, nucleus size variation, necrolysis/autolysis, autolysis/
fibrosis, lobular inflammation, septal inflammation in exocrine
pancreas; peripancreatic fat inflammation.
Statistical analysis
Data are the means 6 S.E. for the number of observations
indicated. Statistical significance and differences between means
were assessed by Student’s t-test with Bonferroni correction for
multiple analyses as appropriate in Excel (Microsoft).
Results
Liraglutide and exendin-4 restrict weight gain, but
liraglutide is more effective at maintaining glucose
tolerance in high fat diet-fed mice
Administration of a high fat (60% fat) diet (HFD) led to marked
weight gain in mice as expected (Fig. 1A, B, C;). Correspondingly,
glucose tolerance was impaired, with an increase in the area under
the curve (AUC) of 56.864.9% (p#0.001, n=16 per group) vs
mice maintained on a normal chow diet (Fig. S2). We chose doses
and administration routes of liraglutide, exendin-4 and sitagliptin
that were previously shown to be effective in mice [27,47,48].
Neither liraglutide, exendin-4, nor sitagliptin exerted any effect on
weight gain or glucose tolerance in mice maintained on a normal
chow diet (Fig. 1). Administration of liraglutide and exendin-4 led
to a 23.963.0% (p#0.01, n=4 per group) and a 37.465.0% (p#
0.01, n=3 per group), decrease in weight gain in mice on a high
fat diet over the course of the drug regimen, respectively (Fig. 1A,
B). Administration of liraglutide led to an improvement in glucose
tolerance in HFD mice at the end of the 75 days’ treatment period
(26.362.1% decrease in AUC vs mice high fat diet that had been
administered saline, p#0.01), such that glucose tolerance was
indistinguishable from that observed in mice maintained on a
normal diet (Fig. 1D, G). In our hands, neither exendin-4 nor
sitagliptin improved glucose tolerance in mice maintained on HFD
by the end of the treatment period (Fig. 1E–F, H–I).
Long term adminstration of liraglutide, exendin-4 and
sitagliptin exert differing effects on beta-cell mass but no
effect on alpha-cell mass
Pancreatic beta- and alpha-cell mass (Fig. 2A) were quantified
in pancreatic slices as described under Materials and Methods.
Administration of liraglutide markedly lowered beta-cell mass in
mice maintained on a normal chow diet (3969.8%, p#0.01, n=3
per group) or high fat diet (62.264.5%, p#0.001, n=4 per group)
vs control mice (Fig. 2B).Administration of exendin 4 had effect on
beta cell mass (Fig. 2C). Interestingly, whilst a HFD alone exerted
no effects on beta-cell mass in the absence of drug treatment,
administration of sitagliptin led to the unmasking of an action of
HFD to increase beta cell mass (40.6%, p#0.01, n=4 per group),
when compared with mice treated with the drug on a normal
chow diet (Fig. 2D). No observable differences in alpha-cell mass
were found between any of the cohorts (Fig. 2E–G).
Long term administration of liraglutide, exendin-4 and
sitagliptin lead to increased Reg3b immunoreactivity
Administration of liraglutide, exendin-4 and sitagliptin led to
increased Reg3b immunoreactivity to differing extents in mouse
pancreata, and depending on diet (Fig. 3A–D). Thus, the increase
in Reg3b signal area associated with administration of liraglutide
to mice on a normal diet was 3.360.6- fold (p#0.001, n=3 per
group) (Fig. 3B). Interestingly, administration of liraglutide did not
exacerbate the effects of high fat diet alone (Fig. 3B). Administra-
tion of exendin-4, on the other hand, led to a signal increase of
5.860.8-fold (p#0.001, n=4 per group) in the Reg3b signal in
mice on high fat diet (Fig. 3C), as well as in ND animals.
Administration of sitagliptin to mice on normal diet resulted in a
3.960.9-fold increase in Reg3b signal (p#0.05, n=3 per group),
and this increase was of 18.666.6-fold (p#0.01, n=4 per group)
in mice on high fat diet (Fig. 3D).
Clinical measures of pancreatitis
There were no statistically significant changes in plasma
amylase activity in mice that were administered liraglutide or
exendin-4 vs mice administered saline (Fig. 3E). However,
administration of sitagliptin to animals on normal diet led to a
1.4-fold increase in amylase activity (p#0.01, n=3 per group) and
a 1.3- fold increase in mice on a high fat diet (p#0.01, n=4 per
group) (Fig. 3E).
There were no detectable differences in plasma lipase activity in
mice on a normal chow diet administered any of the three drugs
when compared to animals administered saline (Fig. 3F). Likewise,
there was no significant change in plasma lipase activity in mice
that were administered saline on a high fat diet vs normal diet
(Fig. 3F). Furthermore, administration of liraglutide and exendin-4
in combination with a high fat diet also failed to affect plasma
lipase activity. We observed no detectable changes in plasma lipase
activity in animals maintained on a normal chow diet and
administered any of the three drugs when compared to animals
administered saline (Fig. 3F).
Histopathological analysis revealed no significant differences in
pathological status of pancreatic slices from the different treatment
groups, with a potential indication of an increase in inflammatory
response in mice subjected to a high fat diet vsmice that have been
maintained on a normal chow diet (Fig. S3).
Discussion
Animal studies do not necessarily predict with certainty what
will happen in humans during similar treatment protocols [50].
Nonetheless, given the poor prognosis for patients diagnosed with
pancreatic cancer, and the lack of risk data from long term studies
of patients on these treatments, there is a need to examine the risk
of pancreatitis following long-term treatment with GLP-1 receptor
agonists in model systems. To circumvent some of the potential
problems involved with studying human disease risk in mouse
models, we have selected a model which reflects at least several key
Figure 2. Long term adminstration of exendin-4, liraglutide and sitagliptin exerts different effects on beta-cell mass but no effect
on alpha-cell mass. Representative images of pancreatic sections stained for insulin (green), glucagon (red) and nuclei (DAPI, blue) (A). Pancreatic
sections from mice treated with liraglutide (B, E), exendin-4 (C, F) and sitagliptin (D, G) were examined. Beta-cell mass (B, C, D), and alpha-cell mass (E,
F, G) were measured from whole section scans as described in ‘Materials and Methods’. p#0.001, ***; p#0.01, n = 3–7 mice.
doi:10.1371/journal.pone.0104873.g002
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elements of T2D in humans [44]. Importantly, we have
administered drugs to mice that already exhibit glucose dysho-
meostasis, in contrast to a recent study [39] whereby liraglutide
was administered prior to the start of the high fat diet regimen.
Of the three agents tested, liraglutide, at the dose tested here,
was overall the most effective at decreasing weight gain and
improving glucose tolerance by the end of the 75 days’ treatment
(Fig. 1). Interestingly, this change was accompanied by a decrease
in beta-cell mass in mice on both normal chow diet and high fat
diet (Fig. 2B). These data are consistent with a recent report
showing that mice administered liraglutide and maintained on a
high fat diet for six weeks, exhibited decreased beta-cell mass
possibly due to improved insulin sensitivity [39]. Interestingly,
mice on a high fat diet in the earlier study by Ellenbroek and
colleagues [39] remained normoglycaemic throughout the study,
since they were given liraglutide prior to starting the high fat diet
regime. More closely mimicking the use of the drug in man, our
mice were rendered hyperglycaemic prior to drug administration
and the drug regimen was longer than that reported in [39].
Suggesting these differences in protocol may be important [39], we
saw no changes in alpha-cell mass during liraglutide treatment in
the present studies. By contrast, neither exendin-4 nor sitagliptin
exerted any effect on beta-cell mass in the present study, albeit
under conditions here where neither drug exerted significant
effects on glucose homeostasis.
In this study we administered sitagliptin by intraperitoneal
injection as daily oral gavages were impractical and would mean
increasing the number of mice we needed to use per cohort, with
the associated ethical issues. Administration by admixture was
prohibitively costly. To assess the efficacy of adminstration of
sitagliptin by intraperitoneal injection, we measured plasma GLP-
1 levels one hour after co-injection of glucose (1 g/kg) and
sitagliptin (10 mg/kg), and demonstrated that this was effective at
raising plasma GLP-1 content, vs saline control (Fig. S1C).
An important prompt for the present investigation was the
controversy that exists over whether long term administration of
GLP-1 mimetics may lead to pancreatitis and pancreatic cancer.
One confounding factor may be the propensity for rodent models
to develop spontaneous pancreatic lesions [51]. Our observations
indicate that rodents may indeed manifest signs of spontaneous
pancreatic lesions but that some of the signals for pancreatic
disease are exaggerated by exposure to the GLP-1 mimetics and
DDP 4 inhibitor drug class (Fig. 3, Fig. S1). We have also observed
that prolonged exposure to high fat diet has a tendency to lead to
increased Reg3B immunoreactivity (Fig. 3B–D) even though there
were no signs of overt clinical pancreatitis. Clinical pancreatitis is
indicated by increases in the activity of both plasma amylase and
lipase. Although we saw increased pancreatic content of Reg3B, a
marker of pancreatitis, by immunohistochemical analysis, with all
three GLP-1 mimetics used in this study (Fig.3A–D), we did not
observe increases in plasma amylase or lipase with administration
of liraglutide and exendin-4 in conjunction with the high fat diet
(Fig. 3E-F). Administration of sitagliptin led to an increase in
amylase activity when administered to mice on both normal chow
diet and high fat diet (Fig. 3E). Histopathological analysis did not
indicate an increased signal for pancreatitis from drug treatment
(Fig. S3). The apparent discrepancy from the four methods of
assessing pancreatitis may be explained by the relative sensitivities
of the methods. Histopathology is a subjective method of analysis
of the pancreas and, whilst we think it is a valuable assessment
tool, we wanted 1) a more quantitative way for assessing
pancreatitis, and 2) more than one method to assess pancreatitis.
We therefore chose to also assess pancreatitis by measuring
pancreatic Reg3b content, and plasma amylase and lipase content.
Reg3b is an indicator of tissue regeneration and is upregulated
when pancreata are damaged e.g. by pancreatitis. Thus, a change
in the content of this protein in the pancreas can be a measure for
mild pancreatitis, where pancreatic tissue is available for analysis.
Assessment of changes in plasma amylase and lipase in mild
pancreatitis is difficult as these can be cleared by the renal system;
this is problematic for early diagnosis of pancreatitis, but is the
only measure available in the clinic where pancreatic material is
not available for analysis.
Thus, our current data do not suggest a clinical lesion, as
defined in the human setting. However, as we observed an effect of
sitagliptin to increase two out of our three measures for
pancreatitis, longer term studies which follow larger cohorts of
mice until the end of their natural life may shed more light on the
risk for pancreatitis and pancreatic cancer in this model.
Supporting Information
Figure S1 Mice were rendered glucose intolerant fol-
lowing 8 weeks on a high fat diet. Time course (A) and area
under the curve (B) of 16 week old male C57BL/6 mice on high
fat diet (HFD) and normal diet (ND) after 8 weeks on differential
diet. (C) Plasma was extracted from mice 1 h following
intraperitoneal injection of glucose (1 g/kg) and saline or
sitagliptin (10 mg/kg), and plasma GLP-1 was measured as
described in [45].
(TIF)
Figure S2 Manual verification of macro calculations.
The percentage of Reg3b positive areas out of 10 (manual; A) and
20 (macro; B) randomly chosen fields from pancreatic sections
from mice treated with saline or exendin-4 were scored by visual
examination. In the manual verification, a field was considered
positive when there was at least one positive signal within the
optical field regardless of area of signal. ND, normal chow diet;
HFD, high fat diet.
(TIF)
Figure S3 Histopathology report. Analyses were carried out
as described in ‘Materials and Methods’. Numbers in brackets
indicate number of positive observations by the total number of
observations made.
(TIF)
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